Analysis of colorectal cancer patients at Xijing Hospital since 2011

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze clinical pathological differences, treatment approaches, and prognosis among colorectal cancer patients who underwent surgery at Xijing Hospital. It includes patients diagnosed with various forms of colorectal adenocarcinoma, including hereditary syndromes. The study will utilize comprehensive medical records and pathological information to identify trends and outcomes in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
* 2\. Visit our center with complete medical records and pathological information;
* 3\. Colorectal cancer patients diagnosed between 2013 and 2023.

Exclusion Criteria:

* 1\. The patient has other colorectal malignancies other than adenocarcinoma;
* 2\. Malignant tumors adjacent to organs invading the colon and rectum;
* 3\. Malignant tumors from distant organs metastasize to the colon and rectum;
* 4\. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.

Where it's running

• Fourth Military Medical University
  Xi'an, Shaanxi, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Using plasma ctDNA methylation to guide adjuvant chemotherapy for high-risk T3N0 colorectal cancer

  This will test whether a blood ctDNA methylation test can help choose stronger chemotherapy after surgery for people with high-risk T3N0 (stage II) colorectal cancer who are ctDNA-positive one month after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562711

• Plasma ctDNA methylation-guided adjuvant chemotherapy for people with T4N0 and low‑risk stage III colorectal cancer.

  This trial will test whether using a blood test (plasma ctDNA methylation) to guide 3 vs 6 months of adjuvant chemotherapy or to switch regimens helps people with T4N0 or low‑risk stage III colorectal cancer after surgery.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562503

• Plasma ctDNA methylation–guided adjuvant chemotherapy for high-risk stage III colorectal cancer

  This trial will test whether adding bevacizumab to standard FOLFOX or CAPOX chemotherapy based on plasma ctDNA results helps adults with high-risk stage III colorectal cancer (T4N+ or T1-3N2).

  Recruiting Phase 2 Fudan University · Shanghai · NCT07562490

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.